Kupke Paul, Kupke Laura S, Glehr Gunther, Evert Katja, Einspieler Ingo, Hornung Matthias, Stroszczynski Christian, Geissler Edward K, Schlitt Hans J, Hutchinson James A, Werner Jens M
Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
Department of Radiology, University Hospital Regensburg, Regensburg, Germany.
Int J Surg. 2025 Jun 1;111(6):4086-4089. doi: 10.1097/JS9.0000000000002422. Epub 2025 Apr 25.
Soluble CD46 (sCD46) has recently been shown to be an effective biomarker of steatotic liver disease (SLD), which is highly prevalent in the western world. Since SLD directly affects outcomes after major hepatectomies and liver transplantation, accurate appraisal of this condition is crucial before liver surgery. In the present study, we asked whether sCD46 measurement in patient plasma could augment the pre-surgical prediction of SLD performed by contrast-enhanced computed tomography. Our data show that combined performance of these tests reveals an area under the curve for the prediction of high-grade SLD of 0.956. After cross-validation, our clinical score leads to an accuracy of 95.12% to detect severe steatosis. Therefore, sCD46 is a promising biomarker for optimizing pre-surgical decision-making assessments, with the aim to identify patients that could benefit from alternative treatment options.
可溶性CD46（sCD46）最近被证明是脂肪性肝病（SLD）的一种有效生物标志物，这种疾病在西方世界非常普遍。由于SLD直接影响大肝切除术后和肝移植后的预后，在肝脏手术前准确评估这种情况至关重要。在本研究中，我们探讨了检测患者血浆中的sCD46是否能增强通过对比增强计算机断层扫描进行的SLD术前预测。我们的数据表明，这些检测的联合表现显示预测高级别SLD的曲线下面积为0.956。经过交叉验证，我们的临床评分检测严重脂肪变性的准确率为95.12%。因此，sCD46是一种很有前景的生物标志物，可用于优化术前决策评估，旨在识别可能从替代治疗方案中获益的患者。
